IMPROVED USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA Russian patent published in 2022 - IPC A61K38/48 A61K9/08 A61P43/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely neurology, dentistry and therapy, and is intended for the treatment of a disease or condition associated with sialorrhea or increased saliva production. For the treatment of a disease or condition associated with sialorrhea or increased saliva production, a botulinum neurotoxin of serotype A is used in the patient. The said botulinum neurotoxin is injected into the parotid glands and submandibular glands, and the ratio between the doses of botulinum neurotoxin injected into each of the parotid glands and each of the submandibular glands ranges from 1.45:1 to 1.7:1. Botulinum neurotoxin is administered in at least two consecutive treatment cycles and the time interval between two consecutive cycles treatment lasts from 10 to 20 weeks. The said botulinum neurotoxin is injected into one site of each submandibular gland and into one site of each parotid gland.

EFFECT: use of the group of inventions provides a significantly reduced number of side effects, including the phenomenon of “dry mouth”, as well as an excellent long-term effect, despite a decrease in the number of injections, which is less painful and burdensome for the patient.

12 cl, 5 dwg, 8 tbl, 7 ex